+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effects of aging, diabetes mellitus, and antiplatelet drugs on growth factors and anti-aging proteins in platelet-rich plasma



The effects of aging, diabetes mellitus, and antiplatelet drugs on growth factors and anti-aging proteins in platelet-rich plasma



Platelets 30(6): 773-792



As the aged population continues to markedly increase worldwide, the incidences of diabetes mellitus (DM) and cardiovascular disease (CVD) are increasing. In this study, we investigated the effects of aging, DM, and antiplatelet drugs on growth factors and anti-aging proteins in platelet-rich plasma (PRP). The study participants were classified into the following four groups: Group A, healthy individuals aged ≤45 years; Group B, healthy individuals aged >45 years; Group C, DM patients aged >45 years; and Group D, CVD patients aged >45 years taking antiplatelet drugs. The concentrations of epidermal growth factor (EGF), fibroblast growth factor (FGF)-2, platelet-derived growth factor (PDGF)-AA, PDGF-AB/BB, vascular endothelial growth factor (VEGF)-A, tissue inhibitor of metalloproteinase 2 (TIMP2), insulin-like growth factor 1 (IGF-1), growth differentiation factor (GDF)11, and clusterin in PRP samples were determined to analyze the effects of aging, DM, and antiplatelet drugs. Overall, the concentrations of IGF-1, TIMP2, and clusterin did not vary significantly between the four groups. The concentrations of PDGF-AB/BB (P = 0.010), VEGF-A (P = 0.000), and GDF11 (P = 0.026) were significantly different between Group A and Group B. Further, the concentrations of EGF (P = 0.000) and GDF11 (P = 0.000) were significantly different between Groups B and C. The concentrations of EGF (P = 0.001), VEGF-A (P = 0.000), and GDF11 (P = 0.002) significantly differed between Groups A and C. The concentrations of FGF-2 (P = 0.048), PDGF-AA (P = 0.03), and GDF11 (P = 0.001) were significantly different between Groups B and D. The concentrations of PDGF-AB/BB (P = 0.032), VEGF-A (P = 0.010), and GDF11 (P = 0.02) significantly differed between Groups A and D. We found that PRP contains high concentrations of the growth factors, TIMP2 and GDF11. Aging, DM, and antiplatelet drugs can decrease the concentration of some growth factors and GDF11, which weakens the regenerative capacity and anti-aging effects of PRP and reduces the quality of PRP.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065940027

Download citation: RISBibTeXText

PMID: 30252623

DOI: 10.1080/09537104.2018.1514110


Related references

Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF). International Journal of Implant Dentistry 2(1): 19, 2016

Shedding light in the controversial terminology for platelet-rich products: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), platelet-leukocyte gel (PLG), preparation rich in growth factors (PRGF), classification and commercialism. Journal of Biomedical Materials Research. Part a 95(4): 1280-1282, 2010

The comparison of platelet-rich fibrin and platelet-rich plasma in releasing of growth factors and their effects on the proliferation and differentiation of adipose tissue-derived stem cells in vitro. Hua Xi Kou Qiang Yi Xue Za Zhi 30(6): 641, 2012

Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report. International Journal of Oral and Maxillofacial Implants 20(1): 118-123, 2005

Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties. Journal of Periodontology 78(4): 661-669, 2007

The Future of Platelet Concentrates in Sports Medicine Platelet-Rich Plasma, Platelet-Rich Fibrin, and the Impact of Scaffolds and Cells on the Long-term Delivery of Growth Factors. Operative Techniques in Sports Medicine 19(3): 190-197, 2011

Effects of Plasma Rich in Growth Factors and Platelet-Rich Fibrin on Proliferation and Viability of Human Gingival Fibroblasts. Journal of Dentistry 12(7): 504-512, 2015

Comparison of the Regenerative Effects of Platelet-Rich Fibrin and Plasma Rich in Growth Factors on Injured Peripheral Nerve: An Experimental Study. Journal of Oral and Maxillofacial Surgery 76(8): 1823.E1-1823.E12, 2018

Effects of antihypertensive drugs in the prevention of new-onset diabetes mellitus in patients with hypertension at high-risk of cardiovascular events in relation to aging. Journal of the American Geriatrics Society 58(2): 395-396, 2010

Platelet function in platelet rich plasma and washed platelets from patients with diabetes mellitus. Federation Proceedings 41(4): ABSTRACT 5536, 1982

Modification of platelet adhesion by antiplatelet drugs helps prevent cardiovascular complications of diabetes mellitus. Medical Hypotheses 18(2): 119-128, 1985

Spontaneous platelet aggregation in whole blood in patients with diabetes mellitus comparison with results in platelet rich plasma. Journal of the Japan Diabetes Society 35(4): 309-315, 1992

Diabetes mellitus and anti-aging. Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 45(2): 152-154, 2008

Effect of Use of Platelet-Rich Plasma (PRP) in Skin with Intrinsic Aging Process. Aesthetic Surgery Journal 38(3): 321-328, 2018

Crevicular Fluid Growth Factors Release Profile Following the Use of Platelet-Rich Fibrin and Plasma Rich Growth Factors in Treating Periodontal Intrabony Defects: A Randomized Clinical Trial. Journal of Periodontology 87(6): 654-662, 2016